Objectives: To compare the clinical and economic outcomes of EVICEL (Ethicon, Inc., Somerville, NJ) and TISSEEL (Baxter Healthcare Corporation, Westlake Village, CA) use in patients undergoing primary coronary artery bypass graft (CABG) surgery. Economic outcomes compared included hospital length of stay, hospital costs, and 30-day readmission rates. Propensity-score matching was used to control for patient and hospital characteristics. Measurements and Main Results: A total of 129,014 primary CABG surgery patients were identified; 986 patients (mean age: 64 years, 73% male) received EVICEL and 6,340 patients (mean age: 65 years, 75% male) received TISSEEL on the index day. After propensity-score matching, patients who received EVICEL compared with TISSEEL had significantly fewer postoperative bleeding complications (3.0% v 5.0%, p ¼ 0.0197), index-day blood transfusion rates (19% v 34%, po0.0001), readmission rates (18% v 32%, po0.0001), and costs ($40,736 [standard deviation $19,465] v $46,005 [standard deviation $24,049], po0.0001). Results from a sensitivity analysis using a generalized linear model to control for other hemostatic agent use also favored EVICEL over TISSEEL. Conclusion: Results from this real-world retrospective database analysis showed fewer bleeding complications and lower costs in patients undergoing primary CABG surgery who received EVICEL compared with TISSEEL.
IN 2010, AN ESTIMATED 395,000 coronary artery bypass graft (CABG) surgeries were performed in the United States. 1 Morbidity and mortality rates are increased in cardiac surgery patients who experience bleeding complications. 2 Bleeding events associated with cardiac surgery are frequent, with estimates suggesting that 10% to 15% of the blood supply in the United States is consumed by cardiac surgery patients. 3 Cardiac surgery patients who experience bleeding-related complications have longer intensive care unit and hospital stays and higher hospital costs compared with cardiac surgery patients who do not experience bleeding-related complications. 4 Cardiac surgery patients requiring blood transfusions have been found to have longer times to extubation, longer intensive care unit stays, more postoperative complications, and higher mortality than patients not requiring blood transfusions. 5 Several strategies can be used to control bleeding in the intraoperative and postoperative periods. Conventional surgical strategies such as manual compression, suture ligation, and cauterization commonly are used to control bleeding during surgery. Prophylactic and therapeutic approaches also are used to decrease the risk of postoperative blood transfusion. 6, 7 However, in some situations, these conventional methods are impractical or ineffective, and additional strategies are required. 8 Topical hemostatic agents such as fibrin sealants are another option to control bleeding during surgery. 9 Fibrin sealants contain both fibrinogen and thrombin 10 and work by mimicking the final stages of the blood coagulation process. 9 Fibrin sealants are used to promote hemostasis in patients undergoing a broad range of surgical procedures, such as cosmetic, cardiovascular, head and neck, neurologic, orthopedic, noncardiac thoracic, and vascular surgery. They are effective across a broad range of bleeding circumstances, such as venous oozing, diffuse raw surface bleeding, and hemorrhage from anastomotic graft sites during vascular surgery. 8, 10 At the site of bleeding, fibrin sealants increase the local concentration of fibrinogen and thrombin; the thrombin cleaves the fibrinogen to fibrin, which polymerizes and crosslinks, progressing from a soluble mesh to a stable clot.
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Little is known about the real-world clinical and economic outcomes of patients treated with fibrin sealants during cardiac surgery. Such data increasingly are being requested by healthcare decision makers who make policies and payment decisions. 12 To the authors' knowledge, no real-world studies have compared the clinical outcomes and economic burden of patients treated with the fibrin sealants EVICEL (Ethicon, Inc., Somerville, NJ) and TISSEEL (Baxter Healthcare Corporation, Westlake Village, CA). Among the available forms of fibrin sealants in the United States, EVICEL and TISSEEL have the same function (hemostatic) and source (human pooled plasma). 13 A detailed comparison of these 2 products is described in Appendix 1. A few studies have compared the properties of EVICEL versus TISSEEL and clinical implications of the differences. Hickerson et al 16 suggested that the superior clot strength and resilience obtained with EVICEL relative to TISSEEL may be due to the difference in factor XIII concentration. Other differences include the higher thrombin activity in the EVICEL formulation and the presence of plasminogen and aprotinin in the TISSEEL formulation. 16 The objective of this study was to compare the clinical outcomes (eg, postoperative bleeding events), healthcare resource utilization (eg, hospital length of stay [LOS] and blood transfusion number), and costs between patients who received EVICEL or TISSEEL during CABG surgery.
Methods

Data Source
The Premier Prospective hospital data set contains information from more than 700 hospitals throughout the United States (www.premierinc.com), covering an estimated 20% of hospital discharges. Data elements include hospital and patient identifiers, primary and secondary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis coding system diagnoses and procedure codes; LOS; admission types and primary payer information. Also available are data elements for patient demographic characteristics, such as age and race, and hospital characteristics, such as provider geographic location, hospital bed size, teaching hospital status, and hospital location.
Patient Selection
Adult patients 18 years or older who underwent primary CABG surgery from January 2009 to March 2014 and received either EVICEL or TISSEEL during the primary CABG surgery were identified in the Premier database. Patients who underwent a CABG procedure were identified using the ICD-9 procedure codes (Appendix 2). Patients were excluded if they received both EVICEL and TISSEEL at any time during the same hospitalization or underwent both CABG and valve surgeries during the same hospitalization. Patients with incomplete hospital stay data (admission and discharge day) during the study time frame also were excluded.
Measures
Outcomes
Clinical outcomes evaluated included bleeding complications (ICD-9 diagnosis 998.1: hemorrhage or hematoma or seroma complicating a procedure) after CABG surgery and blood transfusions during 3 time frames. ICD-9 diagnosis codes (99.0x, V58.2), standard charge codes, and current procedural terminology codes were used to identify clinical outcomes during the following 3 time frames: (1) entire index hospitalization, (2) day of index CABG surgery, and (3) after index hospitalization. Economic outcomes evaluated included hospital overall LOS (ie, number of days from hospital admission until discharge), total hospitalization costs, and 30-day readmission rate. 
Statistical Analysis
Statistical tests were performed to compare demographic, clinical, and hospital characteristics between patients who received EVICEL or TISSEEL. Student t-tests were performed to compare continuous variables; chi-square tests were used to compare categorical variables. A propensity-score matching method was used to match patients who received either EVICEL or TISSEEL on the basis of characteristics including age, sex, race, payer, admission method, Charlson Comorbidity Index, APR-DRG severity of illness and mortality, anemia, anemia caused by cancer, hospital size, geographic region, and teaching status. Hospital location (rural v urban) was not included because 100% of patients were from urban hospitals within both study groups. A propensity score of the probability of using hemostatic treatment (EVICEL v TISSEEL) was created for each patient in the study cohort, and 1 TISSEEL patient was selected for each EVICEL patient (ie, matched at a 1:1 ratio) using the nearest-neighbor method. 20 Additional sensitivity analyses were performed via regressions to control for differences in the use of hemostatic agents other than EVICEL and TISSEEL during the index CABG surgery within the propensity-score-matched cohorts. The following adjusted outcomes were reported: bleeding complication rate, blood transfusion rate, total hospital costs, and 30-day readmission rate. A 2-sided p value of o 0.05 was considered to be statistically significant.
All data used in this analysis were compliant with the Health Insurance Portability and Accountability Act.
Results
Patient Sample
A total of 986 patients received EVICEL and 6,340 patients received TISSEEL during the study period (Fig 1) . Patients who received EVICEL, compared with TISSEEL, experienced more comorbid anemia and a slightly higher APR-DRG severity and were more likely to be admitted to the hospital through the emergency department (Table 1) . Compared with patients who received EVICEL, TISSEEL patients were more likely to be admitted to teaching hospitals and hospitals with more than 500 beds (Table 2) .
Outcomes
In unadjusted analyses, patients who received EVICEL were less likely to develop bleeding complications (4% v 6%, p o0.001) and require blood transfusions (41% v 64%, p o0.001, during the entire hospitalization) compared with patients who received TISSEEL (Table 3) . Overall, patients who received EVICEL had lower hospital costs compared with patients who received TISSEEL; there was no difference in LOS between study groups.
After propensity-score matching, there were no statistically significant differences in patient demographics, clinical covariates, or hospital characteristics between the cohorts. The study results remained in favor of EVICEL over TISSEEL after adjusting for the covariates using a propensity score approach. Patients who received EVICEL compared with TISSEEL experienced fewer bleeding complications (3% v 5%, p ¼ 0.0197); lower blood transfusion rates (41% v 53%, po0.0001, during the entire hospitalization); 30-day readmission rates (18% v 32%, po0.0001); and hospital costs ($40,7367 $19,465 v $46,0057$24,049, po0.0001) ( Table 4) .
Results from sensitivity analysis performed using the propensity-score-matched cohort found that the majority of EVICEL-and TISSEEL-treated patients received other hemostatic agents (91% v 77%, po 0.001); the most commonly used additional agent was thrombin. Additional regression analyses were performed to adjust
Discussion
Surgical hemostasis is needed in cardiac surgery to control intraoperative bleeding and thereby reduce morbidity and the related costs from bleeding-related complications. 21 An estimated 30% of cardiac surgery patients will experience a bleeding-related complication. 4 Cardiac surgery patients who experienced bleeding-related complications were found to have longer intensive care unit (4.9 v 2.1 days) and hospital (11.0 v 6.2 days) stays and higher mean total adjusted hospital costs ($39,050 v $28,771 [year 2007 US]) compared with cardiac surgery patients who did not experience bleedingrelated complications. 4 Cardiac surgery patients requiring red blood cell transfusions were found to have significantly longer times to extubation after surgery (8.0 v 4.3 hours, p r 0.001), intensive care unit stays (1.6 v 1.2 days, p r0.001), and hospital stays (7.2 v 4.3 days, p r 0.001); more postoperative complications (p r 0.001); and higher 30-day hospital morality (3.1% v 0 %, pr0.001) compared with cardiac surgery patients not requiring red blood cell transfusions. 5 In addition, a positive correlation was noted for red blood cell transfusion and increased time to extubation, intensive care unit LOS, postoperative LOS, and mortality. Topical hemostatic agents are used by surgeons to help control bleeding, potentially decreasing bleeding-related complications and the need for red blood cell transfusions. The topical fibrin sealants EVICEL and TISSEEL can be used as an adjunct to hemostasis in patients undergoing surgery. These sealants work by replicating the final steps in the coagulation pathway, ultimately resulting in the formation of a stable clot. 11 The stable clots formed after fibrin sealant administration provide sustained hemostasis because they remain at the site of application for up to 2 weeks, a period that well exceeds the critical risk period for postoperative rebleeding.
Although data from randomized controlled clinical trials demonstrated the efficacy of EVICEL and TISSEEL in cardiac surgery, 22, 23 few studies have compared their performance in the real world. Therefore, the authors of this study performed a hospital database analysis to compare clinical and economic outcomes in patients who received either EVICEL or TISSEEL during their primary cardiac surgery. Results from the analyses, after adjusting for covariate differences between the study cohorts, showed that in primary CABG surgery patients, the use of EVICEL versus TISSEEL was associated with fewer postoperative bleeding events, fewer blood transfusions, less utilization of additional resources, and lower hospital costs, even after controlling for the concomitant use of other hemostatic products such as thrombin.
The results of increased hospital costs with increased bleedingrelated complications were similar to the results from the realworld study performed by Stokes et al. 4 In the study by Stokes et al, increased hospital LOS and costs were demonstrated in surgery patients with bleeding-related complications and/or need for blood transfusions. These increased costs were not evident only in cardiac surgery patients but also in patients undergoing spinal, vascular, solid organ, noncardiac thoracic, general, knee/ hip replacement, and reproductive organ surgeries. Although Stokes et al documented increased costs in surgical patients with bleeding-related complications and/or need for transfusions, the effect of hemostatic agent use was not evaluated.
The results of this study need to be considered in the context of several limitations. First, detailed clinical information, such as the location of hemostatic agent application and patient laboratory data, were not available, given that the study was a retrospective database analysis. In addition, because the patients were not assigned randomly to a treatment group, the authors cannot be sure that unrecognized differences did not exist between patients who received EVICEL or TISSEEL. For example, preoperative antiplatelet therapy between the EVICEL and TISSEEL groups was not captured. However, because similar percentages of patients in both groups underwent elective, urgent, and emergency procedures, it may be reasonable to assume that antiplatelet therapy use was similar between the study groups. Future studies, such as prospective randomized trials, are warranted to measure/control for the use of antiplatelet drug or therapy and timing. Second, bleeding complications were identified using ICD-9 diagnosis codes, which may underestimate the actual bleeding complication rate because less-severe complications may not be documented in a patient's medical record and therefore not coded in the database. In addition, some of the bleeding complications identified using diagnosis codes could be misclassified, given that the administrative database originally was for billing instead of research purposes. Third, the causal relationship between fibrin sealant use and the bleeding-related complication rate cannot be established because of the nature of retrospective databases analyses. The observed differences in economic and clinical outcomes identified between EVICEL and TISSEEL administration could not be explained based on the data obtained for this analysis. Additional studies are warranted to further evaluate the differences identified in this analysis. Finally, because this was a retrospective analysis, the authors were unable to evaluate factors that influenced the product administered. Product choice potentially was influenced more by product availability than product characteristics. Future studies should examine factors that affect selection of particular fibrin sealants.
Conclusion
This real-world retrospective study found that patients who received EVICEL had fewer bleeding-related complications and lower costs than patients who received TISSEEL during CABG surgery. The results remained robust after adjusting for the observed differences between study groups. Specifically, within the matched cohorts the authors found that patients who received EVICEL compared with TISSEEL experienced significantly fewer postoperative bleeding complications, lower blood transfusion rates on the day of surgery, lower hospital readmission rates, and lower hospital costs. Future analyses should further evaluate factors that could explain these differences and determine whether these differences are unique to CABG surgery patients. The detailed differences between these 2 fibrin sealants are described in the following:
Plasminogen is the inactive precursor protein to the enzyme plasmin, which is responsible for degrading fibrin clots. The EVICEL manufacturing process includes a specific affinity chromatography step designed to remove plasminogen, making the EVICEL clot inherently more stable, whereas other fibrin sealants, including TISSEEL, use aprotinin, an inhibitor of plasmin to stabilize the formulation. However, aprotinin can diffuse rapidly from the clot in vivo, thus limiting its ability to prevent plasmin-mediated fibrin degradation. 18 Comparing the 2 fibrin sealants, the concentration of plasminogen in EVICEL was reported to be 7 μg/mL, whereas the level of plasminogen in TISSEEL was 40-120 μg/mL. 17 The clinical impact of this difference in plasminogen concentration is unknown.
The primary active components in fibrin sealant formulations are fibrinogen and thrombin. When the 2 components are mixed, thrombin acts on fibrinogen to enzymatically convert soluble fibrinogen to an insoluble fibrin clot, which then is stabilized by the action of factor XIIIa. EVICEL was reported to contain higher levels of FXIII compared with that of Tisseel. 16, 17 This difference in FXIII between the products translated to EVICEL clots having greater mechanical strength and stability in in vitro studies. 16 In heparinized animal models, it was reported that the thrombin concentration of the fibrin sealant inversely correlated with bleeding time and blood loss. 19 The activity of the thrombin component in EVICEL is 800-to-1,200 IU/mL, which is higher than other fibrin sealants that typically have approximately 500 IU/mL. Even though there are quantitative differences in the level of thrombin activity between EVICEL and TISSEEL, the clinical implications of this difference are not understood completely.
EVICEL and TISSEEL have different temperature requirements during clinical use. EVICEL does not have restrictions within a range of 2-to-371C, 14 whereas TISSEEL must be used within a range of 33-to-371C 15 to avoid challenges with fibrin sealant spraying or dripping due to high viscosity at low temperatures. No studies have investigated whether the use of the fibrin sealants at different temperatures could have clinical implications.
APPENDIX 2. CABG PROCEDURES ICD-9 CODES
ICD-9 Diagnosis Codes
Description 36. 10 Aortocoronary bypass NOS 36. 11 Aortocoronary bypass, 1 artery 36. 12 Aortocoronary bypass, 2 arteries 36. 13 Aortocoronary bypass, 3 arteries 36.14 Aortocoronary bypass, 4 arteries 36. 15 Single mammary 36. 16 Double mammary 36. 17 Abdominal coronary artery bypass 36. 19 Bypass anastomosis heart revascularization NOS, not otherwise specified.
